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Abstract 
In England, personal health budgets are part of a growing trend to give patients more choice 
and control over how health care services are managed and delivered. The personal health 
budget programme was launched by the Department of Health in 2009, and a three-year 
independent evaluation was commissioned with the aim of identifying whether the initiative 
ensured better health- and care-related outcomes when compared to conventional service 
delivery. The evaluation used a controlled trial with a pragmatic design to compare the 
experiences of patients selected to receive a personal health budget (personal health 
budget group) with those continuing with conventional support arrangements (control 
group). Just over 1000 individuals were recruited into the personal health budget group and 
1000 into the control group in order to ensure sufficient statistical power. From the analysis 
of the structured outcome tools and cost data, the evaluation found that, over a 12-month 
follow-up period, the use of personal health budgets was associated with significant 
improvement in patients’ care-related quality of life and psychological well-being. Personal 
health budgets did not appear to have an impact on health status, mortality rates or health-
related quality of life over the same period. Using care-related quality of life measured net 
benefits, personal health budgets were cost-effective: that is, budget holders experienced 
greater benefits than people receiving conventional services, and the budgets were worth 
the cost. This evaluation provides support for the planned wider roll-out of personal health 
budgets after 2014 in so far as the localities in the pilot sample are representative of the 
whole country.
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Introduction 
The personal health budget initiative was proposed in the 2008 NHS Next Stage Review as a 
way to encourage the NHS to become more responsive to the needs of patients. It was 
argued that the provision of greater choice to patients around the type and extent of health 
care would ultimately result in improved system efficiencies (HM Government, 2010). The 
2010 White Paper Equity and Excellence: Liberating the NHS re-affirmed the importance of 
ensuring patients are involved in all decision making (HM Government, 2010). Subsequently, 
the Department of Health published two consultations outlining proposals to secure shared 
decision-making over care and treatment (Department of Health, 2012; Department of 
Health, 2010).  
 
The principles underlying the personal health budgets initiative ((Department of Health, 
2009) were drawn from the experience in social care with personal (individual) budgets 
(Glendinning et al., 2008) and include:  
1. Recipients know the resource level of the available within budget. 
2. Patients are encouraged to develop a support/care plan that details how the 
resource will be used to meet their identified needs.  
3. Patients decide how they would like the budget to be managed. There are three 
options: notionally, where the budget is held by the commissioner, but the budget 
holder is aware of the service options and their financial implications; managed by a 
third party; or as a direct payment. 
 
5 
 
Personal health budget pilot programme 
The personal health budget pilot programme was launched by the Department of Health in 
2009 (Department of Health, 2009). An independent evaluation was commissioned to run 
alongside the pilot programme. The overarching aim was to identify whether personal 
health budgets ensured better health and care outcomes when compared to conventional 
service delivery and, if so, the best way for the initiative to be implemented. Of the 64 pilot 
sites involved in piloting personal health budgets, twenty sites were selected to be in-depth 
evaluation sites, with the remainder being wider-cohort sites. The in-depth sites offered 
personal health budgets to individuals with the following health characteristics: long-term 
conditions (including chronic obstructive pulmonary disease (COPD), diabetes and long-term 
neurological conditions; mental health issues; NHS Continuing Healthcare; and stroke. 
 
In this paper we focus on the evaluation of the effectiveness and cost-effectiveness of 
personal health budgets. 
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Method 
The evaluation used a controlled trial with a pragmatic design to compare the experiences 
of people selected to receive personal health budgets with those continuing with 
conventional support arrangements during the study period. Participants were recruited to 
the study in one of two ways, based on how personal health budgets were being 
implemented within the pilot sites.  In some pilot sites the personal health budget group 
was recruited by those health care professionals offering budgets, while a control group was 
recruited by non-participating health care professionals in the same site. Other sites 
randomised patients into either the personal health budget group or the control group (25% 
of participants were randomly assigned).  
 
Data about respondents were collected at baseline (between April 2010 and June 2011, 
after gaining informed consent from participants) and again 12 months later (April 2011 to 
June 2012).  
 
The National Research Ethics Service conferred a favourable ethical opinion for the 
evaluation. Subsequently, the research was given Research Governance management 
authorisation to commence the study in each pilot site. 
 
Data collection 
Figure 1 shows the sequencing of the main quantitative data collection within the in-depth 
pilot sites. 
 
>Insert Figure 1< 
7 
 
A number of validated outcome measures were used in the structured interviews, including:  
 Health-related quality of life was measured using EQ-5D (Euro-Qol) (Dolan et al., 
1995).  
 An early version of the Adult Social Care Outcome Toolkit (ASCOT) measure (Netten 
et al., 2010) that reflected level of need along nine care-related dimensions: 
personal care/comfort; social participation and involvement; control over daily life; 
meals and nutrition; safety; accommodation cleanliness and comfort; occupation 
and usual activities; anxiety; and dignity and respect.   
 Subjective global scale based on the measure used by the Office for National 
Statistics (ONS) in the Integrated Household Survey (IHS) that captured general life 
happiness and satisfaction (Dolan et al., 2010).  
 Psychological well-being as measured by the 12-item version of the General Health 
Questionnaire (Goldberg, 1992).  
 
In addition, demographic and socio-economic information was collected within the 
interviews, as well as information about current circumstances.  
 
Participants’ health condition, clinical indicators and their use of primary health care 
services were gathered from GP records, whilst their use of secondary care was extracted 
from the Hospital Episodes Statistics database (NHS Information Centre). Both sets of data 
were collected at two time-points during the study period: first, around the time of consent 
to explore the previous 12 months’ activity; second, around 12 months after participants 
agreed to take part to gather information for the year following consent. The data collection 
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allowed the evaluation team to explore whether personal health budgets had an impact on 
the use of either primary or secondary care compared to receiving conventional services.   
 
For personal health budget holders, the support/care plan was used to extract information 
about the size of the budget, the deployment of the budget, and the support/services that 
the budget was spent on. Personal health budgets were used to secure an array of services 
and support, such as home care services, transport, complementary therapies, talking 
therapies, physiotherapy, chiropody and psychiatric appointments.  
 
Statistical analyses  
 
Study consent was initially gained from 2,700 people. Some 302 people were excluded from 
the study because: they had not taken part in the baseline (or follow-up) interviews and had 
in effect withdrawn consent before baseline; they were in residential care at baseline; or 
they had died before baseline. The remaining 2,398 cases were suitable for multiple 
imputation. Of these, 158 people died before follow-up and a further five cases were 
excluded because they were aged under 18. This left an active sample of 2,235 cases, with 
1,171 in the personal health budget group and 1,064 in the control group.  
 
To identify the effects of using personal health budgets, it was necessary for the evaluation 
to address four key issues. First, a method was needed to attribute any relevant differences 
between the personal health budgets group and the control group as being due to the use 
of the budget and not any confounding variable (e.g. service restructure). Secondly, we 
needed to be confident that the differences observed were not just due to chance owing to 
9 
 
how participants in each group had been sampled. Thirdly, specific statistical techniques 
would be needed to compensate for a dataset that inevitably contained some missing 
values. Finally, in comparing the costs and benefits of complex interventions such as 
personal health budgets, it was necessary to recognise that we could not collect data on 
every possible impact or detail of implementation. 
 
As regards the first issue, the data collection was designed to allow a difference-in-
difference method to be used. This approach helps to remove any differences between the 
personal health budget and control groups in the level of the outcome or benefit and costs 
indicator at baseline. We compared our outcome indicators at follow-up between the two 
groups after subtracting any difference between the groups in the relevant indicator at 
baseline. The impact measure is therefore the follow-up difference net of any baseline 
difference in the indicator in question. This approach assumes that, without the 
intervention, the situation of the intervention group would change through time (on 
average) by the same amount as the control group. As an additional safeguard against 
selection bias, we also used multiple regression to account for any differences between 
groups in the change in costs and outcomes due to confounding baselines factors (such as 
socio-demographic and socio-economic factors and health status: for example, health 
condition and comorbidities), not use of personal health budgets.  
 
Regarding the second problem, we collected data from samples of people using personal 
health budgets and conventional service delivery. The value of collected indicator variables 
for each group therefore only imperfectly reflects the true value: they are subject to 
statistical noise. For this reason we calculated both parametric (i.e. assumed normally 
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distributed) and non-parametric (bootstrapped) statistical error margins. We thus report the 
statistical significance of the results using the following significance levels for the 
interpretation: either a 10% (p>0.01), 5% (p>0.05) or 1% (p< 0.01) probability that an 
observed effect may have occurred by chance, as reported below. 
 
A multiple imputation approach was used to tackle missing data. This technique uses 
information inherent in the whole data set to predict what the random missing values 
would have been. It requires that the reasons for the data being missing must be accounted 
for by factors that do not have missing values (Rubin, 1987). The pattern of missing data in 
the sample was as follows. Regarding EQ-5D, ASCOT, and GHQ scores, at least some follow-
up outcomes data were available in 1,656 cases (74% of the active sample of 2,235 cases). 
There were 2,104 cases (94%) with at least some service data at follow-up and 2,133 cases 
(95%) with either some follow-up outcomes data or some service data.  
 
To tackle the fourth issue, we needed to make some assumptions, albeit based on 
discussion with study participants about some of the detail. A key assumption in this regard 
was the identification of personal health budgets provided in addition to or as a substitute 
for conventional services. 
 
Cost-effectiveness was assessed by estimating whether the personal health budgets group 
experienced better quality of life than the control group who received conventional service 
delivery, after netting-off the difference in service and support costs between the groups. 
Quality of life (both EQ-5D and ASCOT) was expressed in monetary terms – by applying 
willingness-to-pay thresholds to the quality of life indicators – to allow the netting-off of 
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costs. At the time of writing, the National Institute for Health and Clinical Excellence (NICE) 
operates with willingness-to-pay (WTP) thresholds of between £20,000 and £30,000: that is, 
if an intervention improves a person’s quality of life by an amount corresponding to being in 
full health compared to a state that is no better than being dead over the course of a year, 
the value of this improvement in monetary terms is between £20,000 and £30,000.   
 
Net monetary quality of life at any time is therefore equal to: quality of life level, times WTP 
threshold, minus costs of services used. The estimated probability of this value being 
greater for the personal health budget group at follow-up compared to the control group 
(after subtracting the respective baseline values to account for any baseline differences 
between the groups), can be interpreted as the probability that personal health budgets 
were (more) cost-effective than conventional service delivery.  
 
Sensitivity analysis was conducted regarding assumptions about the costing of services used 
by the personal health budgets group, and about the assumptions used in the multiple 
imputation procedure. We tested the sensitivity of three types of assumptions:  
 Statistical assumptions. For key analyses such as the cost-effectiveness estimates we 
used both parametric and non-parametric (bootstrapping) methods. We found very 
little difference in the results. 
 Costing assumption. On testing the sensitivity of the main results to this assumption, 
we did not find any qualitative impact on the results until quite unrealistic 
assumptions were tried. 
 Multiple imputation. To test the sensitivity of the main results, we first added a 
further five imputations to our main dataset with a different randomly selected seed 
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value, and second, used a variant imputation model. The main results in both 
alternative cases were very similar to the original estimates, with, if anything, slightly 
better statistical significance. In particular, with both the alternative dataset and the 
alternative imputation model, the results for the whole sample analysis indicated 
that personal health budgets were cost-effective on the ASCOT scale at the 5% 
significance level rather than at 10%. 
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Results 
Table 1 shows the primary health condition breakdown by personal health budget group 
and control group at baseline and at 12 months within the active sample.  
 
>Insert Table 1< 
 
Variation in clinical outcomes 
In the sample, the mortality rate overall at follow-up was 7.7%. Rates in the sample were 
slightly higher for the personal health budget group, but this difference was not statistically 
significant (p = 0.109). Mortality rates were higher overall for the NHS Continuing 
Healthcare sub-group than the rest of the sample, at 15.43% overall (12.42% control and 
16.97% personal health budget group sample), but again this difference was not statistically 
significant, suggesting that the use of personal health budgets is not associated with 
differential mortality.   
 
Exploring clinical outcomes for specific conditions, Table 2 shows that personal health 
budgets did not a have significant impact for the diabetes sub-group (HbA1c) or for the 
COPD sub-group (lung-function FEV1) when compared to conventional service delivery.  
 
>Insert Table 2< 
 
Variations in subjective outcomes  
Individuals in the personal health budget group reported statistically significantly improved 
care-related quality of life (ASCOT) and psychological well-being (GHQ-12) compared with 
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people in the control group (see Table 3 and Table 4). However, there was no significant 
difference for health care-related quality of life (EQ-5D) or subjective well-being.  
 
>Insert Table 3< 
 
>Insert Table 4< 
 
Were personal health budgets cost-effective?  
In terms of care-related quality of life (ASCOT), the personal health budget group showed 
greater benefit (quality of life) at less cost, on average, than the control group. As shown in 
Table 5, net quality of life benefit was between £1,520 and £2,690 greater for the personal 
health budget group than the control group, after subtracting baseline differences. For 
example, at the £30,000 threshold, the extra net benefit averaged £2,300 (£1,180 minus -
£1,120) more for the personal health budget group than the control group. The 
improvement in net benefit was statistically significant at the £30,000 WTP threshold and 
above. There was no statistically significant difference in net benefit between the groups 
when using the EQ-5D quality of life measure (Table 6).  Sensitivity analysis supported these 
results: if anything, it showed personal health budgets to be cost-effective using ASCOT at 
higher significance levels. 
 
>Insert Table 5< 
 
>Insert Table 6< 
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Discussion 
In as far as the localities in the sample were representative of the whole country, and 
notwithstanding the methodological challenges in the study, as summarised below, the 
results provide support for the planned national roll-out of personal health budgets. The 
study suggested that personal health budgets had a positive impact on care-related quality 
of life and psychological well-being.  
 
Health and clinical outcomes (other than psychological health) appeared not to be affected 
by the use of personal health budgets. Due to the relatively short follow-up period used in 
this study (one year), it is unsurprising that the underlying health status of patients was 
unaffected. Furthermore, personal health budgets could be seen as a vehicle to effectively 
manage the health condition rather than improve clinical health status.  
 
A largely neutral impact on (recurrent) costs was also found. Overall, the results suggested 
that personal health budgets could cost-effectively improve care-related quality of life 
results, without negative effects on health status.  
 
With the evaluation results available to help inform policy decisions, the Government 
announced (25 September 2012) that £1.5 million will become available to support the roll-
out of the initiative beyond the pilot programme. Previously, the Secretary of State for 
Health had announced that, subject to the evaluation, by April 2014 everyone in receipt of 
NHS Continuing Healthcare (NHS CHC) will have the right to ask for a personal health 
budget, including a direct payment (4 October 2011, Department of Health, 2012). 
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Furthermore, it is planned that the new Clinical Commissioning Groups (CCGs) will be able 
to offer personal health budgets on a voluntary basis more widely.  
Nonetheless, there are a number of limitations that should be acknowledged when 
interpreting these results. Rather than a single intervention, personal health budgets were 
variously implemented, with different models operating in the twenty in-depth pilot sites 
across six patient groups. Personal health budgets were entirely new and a radical 
departure in some areas and the overall structure and processes developed and changed 
during the course of the evaluation. Designing the study selection criteria in advance was 
not always possible. A particular difficulty was in establishing what the personal health 
budget was for and which services could be purchased.  
 
Another tension in the design of the evaluation was between allowing sufficient elapsed 
time after baseline for the effects of personal health budgets to be felt on the one hand, and 
minimising loss to follow-up on the other. The experience from the evaluation of the 
individual budgets pilots in social care (Glendinning et al., 2008) was that a six-month 
follow-up period was unlikely to be sufficient, and so we opted for a main follow-up period 
of one year. As a consequence, although final recruitment rates were good, drop-out rates 
were an issue and potentially impacted on the robustness of the evaluation findings and the 
extent to which results can be extrapolated. The study population was also in the most part 
very frail, with much lower than population-average health status and well-being scores. We 
expected drop-out rates to be higher for this study population as a result, but we could 
argue that the reasons for drop-out are due to baseline factors to a significant extent, and 
are therefore not a source of bias in the evaluation. 
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The quality of the structured interview outcome data was good, particularly the main 
subjective instruments. As we had to rely on local site tracking and records regarding 
mortality data, we were less able to rate its quality. Service data were drawn from a number 
of sources. Where possible, we did not rely on self-reported use; instead, we interrogated 
care plans, medical records and hospital episode statistics. Another issue was the sheer 
range of services and support that could be purchased, which resulted in a number of 
assumptions being made to produce like-with-like cost estimates between personal health 
budget and control groups.  
 
A final consideration is that such a complex intervention presents methodological challenges 
necessarily resulting in the development of appropriate underpinning assumptions. We 
explored the sensitivity of the main findings by re-estimating net benefit differences with 
changes in:  
 Imputation dataset (created by adding further imputations); 
 Imputation models; 
 Budget level that constitute personal health budgets substituting for, rather than 
being provided in addition to, conventional services.  
 
In the main, the sensitivity analysis demonstrated a higher degree of statistical significance 
of the key results. Systemic interventions such as personal health budgets preclude the use 
of fully double-blinded RCTs and, although we used a range of methods to tackle the 
consequences of a more pragmatic design, it is important to be aware of the discussed 
associated limitations. 
Conclusion 
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In conclusion, despite the study limitations, the evaluation did find that personal health 
budgets were cost-effective and had a positive impact on subjective outcomes. Generally, 
the findings provide support for the further implementation of personal health budgets 
after 2014.   
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Table 1. Completed main outcome questionnaires by health condition 
 Baseline Main follow-up 
Personal health budget group 1,141 663 
NHS Continuing Healthcare 153 94 
Diabetes 170 97 
Stroke 116 71 
Mental health 228 105 
COPD 192 140 
Neurological 284 159 
Control group 1,027 678 
NHS Continuing Healthcare 86 61 
Diabetes 235 165 
Stroke 116 83 
Mental health 184 92 
COPD 152 111 
Neurological 262 173 
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Table 2. Change in clinical outcomes between baseline and follow-up  
 Coeff P>t 
HbA1c – Diabetes health cohort  -0.481 0.449 
FEV1 – COPD health cohort  0.069 0.755 
Significance levels: * p<0.10 ** p<0.05*** p< 0.001  
22 
 
Table 3. ASCOT and EQ-5D outcome difference-in-difference, personal health budget 
group, with control factors 
 
 Care-related quality of life 
(ASCOT) 
Health-related quality of 
life (EQ-5D) 
 Coeff Prob Coeff Prob 
PHB group 0.028 0.047** -0.018 0.167 
Age -0.002 <0.001*** -0.001 0.023** 
Male -0.004 0.741 0.011 0.432 
ADL score 2.11E-04 0.813 -0.004 <0.001*** 
Receives benefits -0.014 0.420 0.011 0.427 
Uni/college educ. 0.010 0.701 0.019 0.175 
Intermediate educ. -0.004 0.840 0.022 0.198 
Health condition     
Continuing Healthcare 0.009 0.656 -0.074 0.001** 
Stroke -0.004 0.873 -0.001 0.977 
Diabetes 0.044 0.146 -3.18E-04 0.988 
Mental health 0.042 0.176 -0.012 0.635 
COPD 0.040 0.140 0.016 0.514 
Neurological 0.043 0.215 -0.022 0.298 
Follow-up period 2.90E-04 0.319 2.95E-05 0.889 
Consent date -2.71E-05 0.810 7.55E-05 0.473 
Area cost adjust 0.079 0.564 0.193 0.186 
Area     
Town & fringe 0.026 0.310 0.014 0.639 
Rural 0.019 0.578 0.036 0.114 
Constant 0.385 0.858 -1.501 0.456 
N 2235  2235  
Model F 2.010 0.011** 2.000 0.011** 
Controls - Joint sig 1.670 0.052* 2.110 0.008** 
Significance levels: * p<0.10 ** p<0.05*** p< 0.001  
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Table 4. GHQ-12 and Subjective well-being difference-in-difference, personal health 
budget group, with control factors 
 Psychological well-being 
(GHQ-12) 
Subjective well-being 
 Coeff Prob Coeff Prob 
PHB group -0.852 0.096* 0.762 0.213 
Age 0.027 0.028** -0.042 0.022** 
Male 1.030 0.059* -0.669 0.110 
ADL score 0.113 0.013** -0.041 0.306 
Receives benefits -0.291 0.604 0.132 0.865 
Uni/college educ. -0.334 0.561 0.446 0.457 
Intermediate educ. 0.288 0.648 -0.755 0.266 
Health condition     
Continuing Healthcare 1.423 0.060* -1.391 0.165 
Stroke -1.801 0.033** 0.569 0.633 
Diabetes -1.891 0.047* 1.563 0.101 
Mental health -0.459 0.653 2.233 0.066* 
COPD -1.278 0.136 1.141 0.350 
Neurological -1.119 0.153 1.015 0.410 
Follow-up period -0.003 0.663 0.014 0.062* 
Consent date -1.57E-04 0.954 0.002 0.611 
Area cost adjust 1.016 0.842 -0.141 0.981 
Area     
Town & fringe -0.549 0.415 0.947 0.295 
Rural -1.048 0.270 1.305 0.166 
Constant -1.188 0.982 -45.595 0.605 
N 2235  2235  
Model F 2.220 0.004** 1.790 0.025** 
Controls - Joint sig 1.880 0.020** 1.590 0.064* 
Significance levels: * p<0.10 ** p<0.05*** p< 0.001  
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Table 5. Difference in mean NMB-change for ASCOT, whole sample, various cost 
effectiveness thresholds 
 
 PHB Control Difference Sig prob 
       
90% 
CI- 
 
90% 
CI+ 
Benefits       
ASCOT change 0.057 0.018 0.039    
£-value of ASCOT change:       
WTP £40,000 2290 720 1570    
WTP £30,000 1720 540 1180    
WTP £20,000 1150 360 790    
WTP £10,000 580 180 400    
Costs       
Cost change 800 1920 -1120    
Net benefit       
NMB change:       
WTP £40,000 1490 -1200 2690 0.057* 410 4970 
WTP £30,000 920 -1380 2300 0.082* 140 4460 
WTP £20,000 350 -1560 1910 0.124 -150 3960 
WTP £10,000 -220 -1740 1520 0.198 -450 3490 
Significance levels: * p<0.10 ** p<0.05*** p< 0.001 
WTP = Willingness- to-Pay  
NMB = Net Monetary Benefit 
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Table 6. Difference in mean NMB-change for EQ-5D, whole sample, various CE thresholds 
 PHB Control Difference Sig prob 
       
90% CI- 
 
90% CI+ 
Benefits       
EQ-5D change -0.011 0.000 -0.011    
£-value of EQ-5D 
change: 
      
 £40,000 -420 0 -420    
 £30,000 -310 0 -310    
 £20,000 -210 0 -210    
 £10,000 -100 0 -100    
Costs       
Cost change 800 1920 -1120    
Net benefit       
NMB change:       
 £40,000 -1220 -1920 700 0.613 -1710 3110 
 £30,000 -1110 -1920 810 0.536 -1450 3060 
 £20,000 -1010 -1920 910 0.459 -1200 3030 
 £10,000 -900 -1920 1020 0.386 -980 3020 
Significance levels: * p<0.10 ** p<0.05*** p< 0.001  
WTP = Willingness- to-Pay  
NMB = Net Monetary Benefit 
 
 
 
